These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22853816)

  • 21. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Tam C; Abruzzo LV; O'Brien S; Wierda WG; Lerner S; Kantarjian HM; Keating MJ
    Cancer; 2009 Jan; 115(2):373-80. PubMed ID: 19117034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia.
    Ferrajoli A
    Leuk Lymphoma; 2009 Mar; 50(3):514-6. PubMed ID: 19347738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.
    Strati P; Tong WG; Vitale C; Wierda WG; O'Brien S; Brown JR; Weng WK; Kipps T; Keating MJ; Ferrajoli A
    Leuk Lymphoma; 2015 Jun; 56(6):1878-80. PubMed ID: 25311497
    [No Abstract]   [Full Text] [Related]  

  • 24. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
    Chang JE; Seo S; Kim KM; Werndli JE; Bottner WA; Rodrigues GA; Sanchez FA; Saphner TJ; Longo WL; Kahl BS
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):379-84. PubMed ID: 21030351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
    Faderl S; Thomas DA; O'Brien S; Garcia-Manero G; Kantarjian HM; Giles FJ; Koller C; Ferrajoli A; Verstovsek S; Pro B; Andreeff M; Beran M; Cortes J; Wierda W; Tran N; Keating MJ
    Blood; 2003 May; 101(9):3413-5. PubMed ID: 12522009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
    James DF; Werner L; Brown JR; Wierda WG; Barrientos JC; Castro JE; Greaves A; Johnson AJ; Rassenti LZ; Rai KR; Neuberg D; Kipps TJ
    J Clin Oncol; 2014 Jul; 32(19):2067-73. PubMed ID: 24868031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Woyach JA; Lin TS; Lucas MS; Heerema N; Moran ME; Cheney C; Lucas DM; Wei L; Caligiuri MA; Byrd JC
    Leukemia; 2009 May; 23(5):912-8. PubMed ID: 19225537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
    Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
    Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
    Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
    J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
    Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
    Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
    Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
    O'Brien S; Ravandi F; Riehl T; Wierda W; Huang X; Tarrand J; O'Neal B; Kantarjian H; Keating M
    Blood; 2008 Feb; 111(4):1816-9. PubMed ID: 18039954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
    Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
    Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.
    Bowen DA; Call TG; Shanafelt TD; Kay NE; Schwager SM; Reinalda MS; Rabe KG; Slager SL; Zent CS
    Leuk Lymphoma; 2010 Apr; 51(4):620-7. PubMed ID: 20302386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
    Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
    Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
    Gruber M; Fleiss K; Porpaczy E; Skrabs C; Hauswirth AW; Gaiger A; Vanura K; Heintel D; Shehata M; Einberger C; Thalhammer R; Fonatsch C; Jäger U
    Ann Hematol; 2011 Oct; 90(10):1131-6. PubMed ID: 21617923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.